Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-05 | Mr. McLaughlin has co-founded two companies: Eyetech Pharmaceuticals, Inc., where he served as Chairman of the board of directors from 2000 until 2006, and Peak Surgical, Inc., where he was a director from 2005 until it was acquired by Medtronic in 2011. Additionally, Mr. McLaughlin has previously served on the board of directors for the following publicly-traded biopharmaceutical companies... He received a B.A. from the University of Notre Dame and a J.D. from Catholic University of America. |
| 2022-04-12 | Mr. McLaughlin has co-founded two companies: Eyetech Pharmaceuticals, Inc., where he served as Chairman of the board of directors from 2000 until 2006, and Peak Surgical, Inc., where he was a director from 2005 until it was acquired by Medtronic in 2011. He received a B.A. from the University of Notre Dame and a J.D. from Catholic University of America. |
| 2023-04-12 | He received a B.A. from the University of Notre Dame and a J.D. from Catholic University of America. |
| 2023-06-20 | John P. McLaughlin, Director |
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-20 | John P. McLaughlin has been a director since September 2019 and Chairman of the Board since October 2019. ... Mr. McLaughlin serves as Chairman of the Board and Dr. Ellison serves as the Company’s President and CEO, as well as a Class III Director. ... We have an Audit Committee which is currently comprised of Messrs. Cooper (Chairman), McLaughlin and Ravich. ... We have a Governance and Nominating Committee which is currently comprised of Mr. McLaughlin (Chairman), Ms. Colleran and Mr. Cooper. ... 2019 Director Compensation ... John McLaughlin ... Total ($) 119,732. |
| 2021-04-30 | John P. McLaughlin has been a director since September 2019 and Chairman of the Board since October 2019. ... Mr. McLaughlin serves as a member of the board of directors of PDL and Lensar, a public medtech company ... We believe that Mr. McLaughlin’s extensive legal, financial, strategic planning, capital raising and executive experience in the life sciences industry, as well as his public company board experience, qualify him for service as a director of our Company. |
Data sourced from SEC filings. Last updated: 2026-03-05